학술논문
A magnifying glass onto renal function and serum lipid evolutions after tenofovir (TDF) and emtricitabine (FTC) in combination with atazanavir/ritonavir (ATV/r) versus efavirenz (EFV) as first-line HAART (the INCA trial).
Document Type
Article
Author
Source
Subject
*BLOOD lipids
*TENOFOVIR
*ATAZANAVIR
*THERAPEUTICS
*
*
*
Language
ISSN
1758-2652
Abstract
7-11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK [ABSTRACT FROM AUTHOR]